THANK YOU FOR SUBSCRIBING
Pharma Tech Outlook | Wednesday, March 24, 2021
Avance Clinical congratulates Atossa Therapeutics on Phase 1 final results for the AT-301 nasal spray being developed for COVID-19.
FREMONT, CA: Avance Clinical, the top Australian biotech CRO and winner of the Frost & Sullivan Asia-Pacific CRO Market Leadership Award, congratulated Atossa Therapeutics on Phase 1 final results for the AT-301 nasal spray being developed for COVID-19.
Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focusing on discovering and developing novel medicines in areas of significant unmet medical requirements, emphasizing breast cancer and COVID-19.
Yvonne Lungershausen, CEO, Avance Clinical, said, "As the CRO for this important study, we congratulate Atossa Therapeutics on these impressive safety and tolerability clinical results. Atossa Therapeutics have tapped the full scope of our CRO services including ClinicReady, our scientific and medical affairs specialist team. Australian clinical trials are recognized globally for their speed and accuracy and the fact that the clinical data is accepted by all major regulatory authorities including the FDA. Increasingly our clients are also tapping the generous 43.5% Australian Government rebate to support their clinical research."
According to Atossa Therapeutics, Atossa Therapeutics recently announced the final results of Phase 1 double-blind, randomized, placebo-controlled clinical trial utilizing Atossa's proprietary drug candidate AT-301, which was administered through a nasal spray. At two different dose levels over 14 days, AT-301 was safe and well-received in healthy male and female participants in this study. AT-301 is being designed to be used at home by COVID-19 patients who have recently been diagnosed. There are currently no FDA-approved home treatments for COVID-19.
According to the study's final report, there were no severe adverse effects, no discontinuations, and no bronchospasms. Only one of the 32 participants in the survey experienced adverse events that were considered moderate in severity, and every other adverse event were deemed mild.
AT-301 nasal spray was found to be safe and well-tolerated in this study, according to Atossa. Nasal pain and sneezing were the most common medication-related adverse effects observed with AT-301 treatment with either single or multiple doses.
"The results from this study are very encouraging and we look forward to quickly commencing the next study of AT-301," commented Steven Quay, M.D., Ph.D., Atossa's President and CEO.
More in News